Oligomerix has received a $3.35m grant from the National Institutes of Health (NIH) unit National Institute on Aging to fund the clinical development of its lead candidate, OLX-07010, for Alzheimer’s disease (AD).
The company intends to commence a Phase Ia clinical trial of OLX-07010 in healthy subjects this year.
Go deeper with GlobalData
The randomised, double-blind, three-part trial will analyse the safety, tolerability and pharmacokinetics of single, multiple ascending doses as well as a single dose of OLX-07010 in healthy elderly subjects.
Such trials are anticipated to facilitate selecting the dosage of the therapy for further proof-of-concept studies in AD and other neurodegenerative diseases.
An oral tau self-association small molecule inhibitor, OLX-07010 acts on the beginning of the tau aggregation cascade.
See Also:
This cascade is a process deemed to be vital for the development of AD, as well as various other neurodegenerative ailments.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn various animal models of tau-mediated neurodegeneration, the therapy showed efficacy.
Furthermore, the preclinical safety studies of OLX-07010 have concluded.
In June this year, the company raised $2.7m in an extension of its Series B financing round to further support preclinical and clinical development of its tau self-association inhibitor portfolio.
The funds will also be used for corporate reorganisation to move into clinical development and first-in-human testing.
Oligomerix CEO and head of discovery James Moe said: “Key requirements for treating early-stage AD include safe, efficacious, and cost-effective therapeutic interventions.
“Based on our preliminary results, this oral small molecule, CNS drug-like lead significantly fulfils these requirements.
“OLX-07010 is a highly differentiated tau self-association inhibitor targeting the beginning of the tau aggregation cascade.”
The company focuses on developing small molecule therapies that act on tau for rare neurodegenerative and Alzheimer’s diseases.
